Evotec SE Stock (DE0005664809): Analyst Targets Span From 4.50 To 10 Euros As Shares Hover Around 4.60

Evotec SE shares are trading around 4.60 euros on Xetra while recent reports highlight a wide analyst price target range between 4.50 and 10 euros and a 37 percent 12-month decline, keeping the MDAX-listed biotech stock in focus.

By AD HOC NEWS - Companies & Analysis Desk Team | June 11, 2026

Evotec SE remains in focus on the German Xetra market, with the stock trading around 4.60 euros in recent sessions as investors weigh a wide analyst price target range and a steep 12-month share price decline. Recent coverage from Boerse Express points to a spread of analyst targets between 4.50 and 10.00 euros per share, underlining divided views on the biotech group’s medium-term prospects. At the same time, Evotec shares have lost roughly 37 percent over the past twelve months, positioning the MDAX constituent among the weaker names in Germany’s mid-cap universe. Against this backdrop, the current price level around the mid-4-euro range sits near the lower end of some analyst estimates while still well below the most optimistic targets.

Analyst target range puts Evotec’s valuation debate into focus

According to a June 9, 2026 update from Boerse Express, cited analyst estimates for Evotec currently span from 4.50 euros at the low end to 10.00 euros at the upper end. This roughly 120 percent range between the lowest and highest target reflects uncertainty about the company’s ability to translate its drug discovery and development platforms into sustained profitable growth. The reported spread also highlights how differently banks and research houses assess Evotec’s execution risks, pipeline value, and cost-saving efforts in the wake of recent strategic changes.

Additional data points from German financial portals show that aggregated targets still stand meaningfully above the prevailing market price. Ariva lists an average price target of about 9.85 euros, which implies an upside of more than 100 percent compared with a current Evotec share price in the 4.60-euro region. While individual analysts may sit closer to the 4.50-euro floor cited by Boerse Express, the mean of published targets suggests that, on paper, many institutions continue to model a scenario where Evotec’s business regains momentum and valuation multiples normalize over time. However, market pricing at a significant discount to that average implies that a large portion of investors either discounts those scenarios or demands a much higher risk premium for the stock.

The same Boerse Express article underscores that Evotec’s share price performance has been weak over the past year, with the stock down about 37 percent in twelve months. That drawdown is consistent with broader concerns around small and mid-cap biotech valuations, rising funding costs and company-specific execution risks. For a contract research and development platform player like Evotec, setbacks in partner projects, delays in clinical milestones or weaker-than-expected order intake can quickly translate into lower confidence in long-term revenue trajectories, which in turn affects how aggressively analysts model future cash flows. The magnitude of the 12-month decline also means that part of the market may now be more focused on downside protection and balance sheet resilience than on long-dated pipeline optionality.

Evotec’s sector classification as a pharma and life-science company with a strong biotechnology angle further shapes analyst thinking. Unlike a single-asset biotech, Evotec operates a platform model aimed at generating recurring fees, milestone payments and, in some cases, royalties from collaborations across multiple partners and therapeutic areas. Analysts must therefore forecast not only the performance of individual late-stage assets but also the company’s ability to win and scale new alliances over time. Differing assumptions regarding partnership momentum, pricing, utilization of its research sites and the impact of cost-reduction programs naturally result in a wide range of price targets, as captured by the 4.50 to 10.00-euro spread.

Valuation metrics underline how sensitive the stock is to growth and profitability expectations. Ariva data show a negative price-earnings ratio (P/E) of roughly -9.4, reflecting that Evotec is currently loss-making on a reported basis. For analysts, that means traditional P/E comparisons to profitable peers are of limited use, and more emphasis falls on enterprise value to sales, pipeline valuation and discounted cash flow models. Small changes in margin assumptions or in the probability of success of partnered projects can materially shift fair value estimates, again contributing to the wide dispersion of targets across the analyst community.

Ownership data from comdirect highlight that Evotec has a relatively diversified shareholder base with a free float of a little over 54 percent and several institutional investors holding mid-single-digit stakes. Listed holders include Excalibur funds with just under 10 percent, MAK Capital with around 7 percent and Mubadala Investment with roughly 6.5 percent, alongside positions held by T. Rowe Price affiliates, Vanguard and Franklin Templeton. For analysts, the presence of long-term institutional shareholders can be a stabilizing factor in the investment case, but it does not necessarily shield the stock from volatility if earnings miss expectations or strategic shifts disappoint. The mix of specialized and generalist investors also influences how quickly sentiment can swing after news on guidance, restructuring or pipeline developments.

Recent commentary on Evotec’s fundamental backdrop centers on its first-quarter numbers, an announced cost-savings program and the upcoming annual general meeting (AGM). As reported by AD HOC NEWS, the stock has been hovering around 4.60 euros while the market digests Q1 results and a savings plan targeting 75 million euros in cost reductions by 2027. Analysts must incorporate the impact of this plan into their models, weighing potential margin uplift against execution risks and possible effects on innovation capacity. If the program delivers the expected efficiencies without undermining research output, some analysts may see scope for upward revisions, which could support the higher end of current target ranges. Conversely, if savings weigh on project delivery or talent retention, more cautious houses may gravitate toward or even below the 4.50-euro lower bound mentioned in the Boerse Express range.

Shorter-term trading updates provide additional context for how the market is positioning into this valuation debate. Intraday reports for June 11, 2026 from finanzen.ch and finanzen.net show that Evotec shares have seen modest moves around the 4.58 to 4.67-euro mark on Xetra during the morning and midday session. At one point, finanzen.ch highlighted the stock among the MDAX losers after a 0.2 percent drop to 4.58 euros shortly after 9:28 a.m., while a later snapshot from the same portal pointed to a 1.7 percent gain to 4.67 euros around 12:28 p.m., moving the share into the group of intraday winners. Finanzen.net likewise reported a decline of roughly 0.3 percent to 4.58 euros in late-morning trading. Taken together, these ticks illustrate typical intraday volatility rather than a decisive trend shift, but they confirm that the current price zone remains anchored in the mid-4-euro range as analysts and investors reassess the outlook.

Additional real-time order book data from FinanzNachrichten show bid and ask levels for Evotec concentrated around 4.62 to 4.64 euros in mid-afternoon Xetra trading, with several small orders stacked across this narrow band. This intraday snapshot suggests relatively tight spreads and sufficient liquidity for retail-sized orders, which is consistent with Evotec’s status as an actively traded MDAX constituent. For analysts, near-term price action within such a range may not alter fundamental views but can influence technical indicators and short-term positioning calls that some research desks publish alongside their longer-term target prices.

Beyond daily fluctuations, analysts must situate Evotec within its competitive landscape and broader sector dynamics. Trading-Treff describes Evotec as a German biotechnology company focused on drug discovery and development, with listings on the Frankfurt Stock Exchange and trading activity referenced on Nasdaq in certain contexts. The company’s business model, which combines proprietary platforms for small molecules, biologics and cell therapies with partnerships across big pharma and biotech, places it somewhere between traditional contract research organizations and pipeline-owning biotechs. Analyst models therefore tend to benchmark Evotec against both contract research peers and innovation-driven biotech names, assessing relative valuation multiples and growth prospects in light of sector-wide funding trends and R&D productivity.

Sector pressure has been visible not only in Evotec’s share price but also in the performance of broader biotech indices, where risk appetite has fluctuated in response to interest rate expectations and deal activity. When financing conditions tighten, investors often demand a clearer path to profitability and stronger balance sheets from platform companies. In that environment, analyst targets may converge toward more conservative scenarios, potentially pulling the average closer to the lower end of the 4.50 to 10-euro band. Conversely, any signs of renewed M&A interest in the space, strong data readouts in Evotec-partnered programs or a faster-than-expected ramp-up in fee-for-service revenue could prompt more bullish revisions and push some targets back toward double-digit levels.

Another factor that can shape analyst sentiment is Evotec’s communication strategy around milestones and financial guidance. Investors increasingly expect detailed breakdowns of segment performance, booking visibility and pipeline catalysts. Clarity around the timing and size of potential milestone income or profit-sharing arrangements can help reduce the dispersion in valuation assumptions. If Evotec provides more granular medium-term guidance or updates its capital allocation framework during the AGM or subsequent investor events, this could give analysts additional inputs to refine their models, potentially narrowing the target range. Until that happens, the current dispersion reflects both the inherent uncertainty in early-stage R&D and differing levels of conviction about management’s ability to execute the cost-savings and growth agenda.

Looking at the balance between risks and opportunities, analysts generally monitor several key themes when framing their price targets for Evotec: execution of the 75 million euro savings program through 2027, the evolution of the order book across therapeutic areas, the performance of partnered clinical assets, and the company’s ability to maintain or expand its network of big pharma customers. Any positive surprise on these fronts can shift the narrative and justify higher fair-value estimates, while setbacks may cause adjustments toward the lower bound of current expectations. For now, the range between 4.50 and 10 euros as reported by Boerse Express captures the breadth of possible outcomes that research houses see for the stock over their typical 12-month horizon.

On the other side of the equation, the roughly 37 percent 12-month share price decline implies that the market has already priced in a substantial amount of caution. Some analysts may interpret this as an opportunity if they believe cost cuts and strategic initiatives can restore growth and improve profitability. Others may argue that, given ongoing sector headwinds and company-specific uncertainties, a discount to historical valuation levels remains justified. The fact that the average target still sits materially above the current price, according to Ariva, indicates that even some relatively conservative models leave room for upside if execution improves. However, the presence of at least one target close to the prevailing market level at 4.50 euros demonstrates that a portion of the analyst community sees limited near-term re-rating potential without clearer evidence of a turnaround.

For US-based retail investors looking at Evotec as an international biotech exposure, the stock’s primary listing on Xetra and inclusion in the MDAX make German market dynamics and euro exchange rates relevant factors. While Ariva notes the ticker symbol EVOTF for trading on certain platforms, the core liquidity remains on the Frankfurt venues. Analyst targets quoted in euros must therefore be contextualized with currency considerations and the specific instruments through which US investors access the name. Research coverage often focuses on the euro-denominated Xetra line, and data providers may translate those levels for over-the-counter trading in the US, but the fundamental valuation work is typically anchored in the home market metrics reported in euros.

In the coming weeks, attention is likely to remain on the AGM and any qualitative or quantitative guidance updates as potential catalysts for analyst revisions. Should management provide more detail on the trajectory of the cost-savings plan, capital allocation priorities or pipeline milestones, sell-side houses may adjust their assumptions, which could either compress or further widen the current 4.50 to 10-euro target range. Until then, Evotec’s share price near 4.60 euros and its position among the weaker performers over the last twelve months set the stage for a valuation debate in which analyst opinions remain clearly divided.

From a market-structure perspective, Evotec’s MDAX membership means that the stock is also exposed to flows from index and ETF investors tracking German mid caps. Changes in MDAX composition, sector allocations or fund flows into European equities can influence trading volumes and volatility in Evotec independently of company-specific news. Analysts occasionally factor such technical and flow-driven aspects into their short-term recommendations and risk assessments, even if their long-term target prices are primarily grounded in fundamentals. As a result, the stock can sometimes move sharply on macro or index-related headlines that have little direct link to Evotec’s own operations, adding another layer of complexity to interpreting price action relative to analyst models.

For now, the key data points framing the discussion are clear: a share price oscillating around 4.60 euros, an average analyst target around 9.85 euros, a reported target range from 4.50 to 10 euros and a 37 percent decline over twelve months. How that gap between current pricing and model-based fair values evolves will depend on the company’s upcoming communication, the progress of its savings plan and any new partnership or pipeline developments that may either reinforce or challenge prevailing assumptions in analyst spreadsheets.

Against this backdrop, Evotec remains a closely watched name within the European biotech and life-science space, with analyst disagreements over fair value mirroring broader market uncertainty around R&D-heavy business models in a shifting macro environment.

In the short term, the stock’s day-to-day moves on Xetra will likely continue to be driven by a mix of news flow, sentiment and technical factors, while medium-term direction will depend on whether management can deliver on efficiency targets and sustain collaboration-driven growth at a level that supports the upper half of the current analyst target range.

For market participants tracking the MDAX and the European biotech segment, Evotec’s wide analyst target dispersion and substantial 12-month price drawdown make it a notable case study in how differing assumptions about execution and innovation can translate into sharply divergent valuation outcomes.

Looking further ahead, any significant new data releases from partnered clinical programs, changes in strategic focus, or large-scale partnership announcements could quickly reshape the analyst landscape, potentially pulling the consensus target closer to the current share price or pushing it further out if confidence in the business trajectory improves.

Until those catalysts materialize, Evotec’s valuation debate remains defined by the currently observed 4.50 to 10-euro analyst target span, its mid-4-euro trading level and a sector environment in which investors and analysts alike are balancing the promise of platform-based drug discovery against the realities of execution and funding cycles.

In this context, US retail investors considering the stock via over-the-counter lines or international brokerage platforms may find it helpful to follow both German-language and English-language coverage, as key developments and analyst revisions are often reported first in the German financial media before being picked up more broadly.

As always in the biotech and life-science sector, the timeline and outcomes of R&D and partnership milestones will be central to determining whether Evotec can close the gap between its current market price and the higher end of the analyst target range highlighted in recent reports.

Until then, the stock’s position near the lower end of that range leaves analysts and investors with a wide spectrum of scenarios to consider, from cautious base cases anchored around 4.50 euros to more optimistic views that see potential for a move toward 10 euros over the typical 12-month analyst horizon.

How the analyst debate feeds into the broader outlook

Looking at Evotec through the lens of analyst valuation debates highlights how strongly expectations shape the narrative around a stock that is still in an investment phase, with negative earnings and a focus on building long-term platform value. The current dispersion in price targets effectively encapsulates different judgments about the timing and probability of that value crystallizing in reported numbers. For observers, following revisions to these targets over time can provide a useful barometer of how sentiment is evolving in response to quarterly updates, strategic decisions and broader sector trends.

From a practical standpoint, market participants will likely continue to watch a few key markers: whether the 4.50-euro floor mentioned among analyst targets remains intact in light of upcoming news, whether the average target moves closer to or further away from the current price, and whether the 37 percent 12-month decline stabilizes or deepens. These elements, combined with the dynamics of MDAX fund flows and biotech sector performance, will frame the ongoing discussion around Evotec’s valuation as the year progresses.

Evotec SE at a glance

• Name: Evotec SE
• Industry: Biotechnology and life-science drug discovery
• Headquarters: Hamburg, Germany
• Core markets: Global pharma and biotech partners in Europe, North America and Asia
• Revenue drivers: Research collaboration fees, milestones and potential royalties from partnered drug discovery and development projects
• Listing: Xetra/Frankfurt, ticker EVT; referenced OTC ticker EVOTF
• Trading currency: Euro (EUR)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.